KEGG   NETWORK: N10007Help
Entry
N10007                      Network                                

Name
Kinase inhibitor to BRAF mutation
Definition
(Vemurafenib,Dabrafenib,Encorafenib) -| BRAF*
  Expanded
(D09996,D10104,D11053) -| 673v1
Class
nt06210 ERK signaling
nt06268 Melanoma
nt06274 Thyroid cancer
Type
Drug target
Gene
673  BRAF; B-Raf proto-oncogene, serine/threonine kinase
Variant
673v1  BRAF mutation
Perturbant
D09996  Vemurafenib
D10104  Dabrafenib mesylate
D11053  Encorafenib
Reference
  Authors
Rahman MA, Salajegheh A, Smith RA, Lam AK
  Title
BRAF inhibitors: From the laboratory to clinical trials.
  Journal
Crit Rev Oncol Hematol 90:220-32 (2014)
DOI:10.1016/j.critrevonc.2013.12.008
Reference
  Authors
Holderfield M, Deuker MM, McCormick F, McMahon M
  Title
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.
  Journal
Nat Rev Cancer 14:455-67 (2014)
DOI:10.1038/nrc3760
LinkDB All DBs

DBGET integrated database retrieval system